DNPUF - Sumitomo Dainippon Pharma Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD

Sumitomo Dainippon Pharma Co., Ltd.

6-8 Doshomachi 2-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6203 5321
http://www.ds-pharma.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Hiroshi NomuraCEO, Pres & Representative DirectorN/AN/A1957
Hisayoshi KashimaSr. Director & Corp. ControllerN/AN/AN/A
Mr. Toru KimuraSr. Exec. Officer, Chief Scientific Officer & DirectorN/AN/AN/A
Ms. Atsuko HiguchiExec. Officer of Corp. Governance, Corp. Communications & HRN/AN/AN/A
Mr. Hitoshi OdagiriExec. VP, Exec. Director of Sales & Mktg. Div., Head of Japan Bus. Unit and DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Corporate Governance

Sumitomo Dainippon Pharma Co., Ltd.’s ISS Governance QualityScore as of December 6, 2019 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.